Gilad 2007

Methods	Randomised, single‐centre, open‐label, parallel‐group trial conducted at Tel Aviv University and Medical Centre, Israel 2 treatment arms: LTG and CBZ
Participants	Adults admitted to the neurological department with a first seizure event after an ischaemic stroke Number randomised: LTG = 32, CBZ = 32 46 male participants (72%) 100% of participants had partial epilepsy Unclear if any participants had received previous AED treatment Mean age (range): 67.5 (38‐90) years
Interventions	Monotherapy with LTG or CBZ for 12 months Dose escalation phase (length not stated) leading to LTG 100 mg/d, CBZ 300 mg/d Range of follow‐up: not stated
Outcomes	The appearance of a second seizure under treatment or by finishing the 12‐month follow‐up without seizures Tolerability: incidence of adverse events Withdrawals due to adverse events
Notes	Contact made with trial author who was willing to provide IPD but data never received. Aggregate data extracted from graphs in the publication. Stated in the title of the paper that LTG and CBZ were monotherapy treatments but Table 1 of the paper refers to Total no. AED, unclear if all participants were receiving monotherapy treatment
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised in a 1:1 ratio, no further information provided
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label trial
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open label trial
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rate reported, all randomised participants included in analysis
Selective reporting (reporting bias)	Low risk	No protocol available. Seizure outcomes and adverse events well reported
Other bias	Unclear risk	Unclear if all participants were receiving monotherapy treatment